KEAP1 and non-small cell lung carcinoma: Despite the well-documented clinical impact of KEAP1 and NFE2L2 mutations [12], the role of aberrant KEAP1 methylation was not fully elucidated in NSCLC, and its clinical prognostic significance in many solid tumors remains controversial [17].